Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 161.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 163.50p
  • 52 Week Low: 101.00p
  • Currency: UK Pounds
  • Shares Issued: 106.69m
  • Volume: 30,263
  • Market Cap: £171.77m
  • RiskGrade: 352

Genus Finance Director sells 43,000 shares

Date: Wednesday 14 Mar 2012

LONDON (ShareCast) - John Worby, Group Finance Director of Genus, the FTSE 250 animal genetics firm, has sold 43,000 shares, half of the amount he vested earlier this month.

Worby sold 43,261 shares at 1,318.41p each for a total of £570,357. The sale was made further to the vesting of 86,523 conditional nil-cost share options on March 5th under the company's performance share plan.

The remaining 43,262 share options that vested under the plan have been retained by Worby.

Towards the end of last month the firm reported strong growth in sales volumes in Asia has seen animal genetics firm Genus increase revenue by almost a 10th in the first half of its financial year.

Furthermore, after reviewing its dividend policy last year, the firm has decided to start paying an interim dividend for the first time this year. The board has approved an interim dividend of 4.5p per share payable on March 30th.

The stock has rocketed in the past past year, rising almost 44%, equivalent to 404p. The share price is up 0.84%, or 11p over the past week.


Top Director Buys

Capital Shopping Centres Group (CSCG)
Director name: Mr John Whittaker
Amount purchased: 300,000 @ 347.24p
Value: £1,041,720

Capital Shopping Centres Group (CSCG)
Director name: Mr John Whittaker
Amount purchased: 300,000 @ 344.55p
Value: £1,033,650

FBD Holdings (FBH)
Director name: Mr Andrew Langford
Amount purchased: 6,818 @ € 9.03
Value: € 61,567

Cello Group (CLL)
Director name: Mr Mark Scott
Amount purchased: 60,500 @ 41.00p
Value: £24,805

Marks & Spencer Group (MKS)
Director name: Ms Miranda Curtis
Amount purchased: 5,500 @ 367.50p
Value: £20,212

BG Group (BG.)
Director name: Mr Caio Koch-Weser
Amount purchased: 1,000 @ 1,533.14p
Value: £15,331

BG Group (BG.)
Director name: Mr Caio Koch-Weser
Amount purchased: 700 @ 1,535.23p
Value: £10,747


Top Director Sells

Rolls-Royce Holdings (RR.)
Director name: Mr Mike Terrett
Amount sold: 287,997 @ 818.25p
Value: £2,356,535

Barclays (BARC)
Director name: Mr Chris Lucas
Amount sold: 613,536 @ 239.88p
Value: £1,471,750

Rolls-Royce Holdings (RR.)
Director name: Mr Colin P Smith
Amount sold: 175,690 @ 818.25p
Value: £1,437,583

Rolls-Royce Holdings (RR.)
Director name: Mr James M Guyette
Amount sold: 113,484 @ 818.25p
Value: £928,583

Genus (GNS)
Director name: Mr John Worby
Amount sold: 43,261 @ 1,318.41p
Value: £570,357

Sage Group (SGE)
Director name: Mr Guy Berruyer
Amount sold: 113,925 @ 297.97p
Value: £339,462

Sage Group (SGE)
Director name: Mr Guy Berruyer
Amount sold: 105,026 @ 300.00p
Value: £315,078

Sage Group (SGE)
Director name: Mr David Clayton
Amount sold: 72,958 @ 297.97p
Value: £217,393

Sage Group (SGE)
Director name: Mr Paul Harrison
Amount sold: 72,660 @ 297.97p
Value: £216,505

Rolls-Royce Holdings (RR.)
Director name: Mr Mark Morris
Amount sold: 24,846 @ 818.25p
Value: £203,302

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 161.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 163.50p
52 Week Low 101.00p
Volume 30,263
Shares Issued 106.69m
Market Cap £171.77m
RiskGrade 352

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
86.02% below the market average86.02% below the market average86.02% below the market average86.02% below the market average86.02% below the market average
Sector averageSector averageSector averageSector averageSector average
Price Trend
81.60% above the market average81.60% above the market average81.60% above the market average81.60% above the market average81.60% above the market average
53.85% above the sector average53.85% above the sector average53.85% above the sector average53.85% above the sector average53.85% above the sector average
Income
76.62% below the market average76.62% below the market average76.62% below the market average76.62% below the market average76.62% below the market average
38.46% above the sector average38.46% above the sector average38.46% above the sector average38.46% above the sector average38.46% above the sector average
Growth
30.41% below the market average30.41% below the market average30.41% below the market average30.41% below the market average30.41% below the market average
47.06% below the sector average47.06% below the sector average47.06% below the sector average47.06% below the sector average47.06% below the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  2nd Interim Interim
Ex-Div 23-Apr-20 03-Oct-19
Paid 22-May-20 01-Nov-19
Amount 1.00p 1.15p

Trades for 07-Aug-2020

Time Volume / Share Price
16:30 618 @ 160.00p
16:03 11,000 @ 160.00p
16:01 8,003 @ 160.00p
15:21 310 @ 160.00p
15:19 8,000 @ 160.00p

Cello Health Key Personnel

CEO Mark Scott

Top of Page